Lewis B. Kinter
About
In The Last Decade
Lewis B. Kinter
96 papers receiving 1.8k citations
Peers
Comparison fields: 5 of 135
- Molecular Biology 490
- Pulmonary and Respiratory Medicine 342
- Social Psychology 285
- Ecology 240
- Cardiology and Cardiovascular Medicine 234
Countries citing papers authored by Lewis B. Kinter
This map shows the geographic impact of Lewis B. Kinter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lewis B. Kinter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lewis B. Kinter more than expected).
Fields of papers citing papers by Lewis B. Kinter
This network shows the impact of papers produced by Lewis B. Kinter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lewis B. Kinter. The network helps show where Lewis B. Kinter may publish in the future.
Co-authorship network of co-authors of Lewis B. Kinter
This figure shows the co-authorship network connecting the top 25 collaborators of Lewis B. Kinter. A scholar is included among the top collaborators of Lewis B. Kinter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lewis B. Kinter. Lewis B. Kinter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Title | Journal | Authors | Indexed citations |
|---|---|---|---|---|
| 1 | Perspectives on using a multiplex human kidney safety biomarker panel to detect cisplatin-induced tubular toxicity in male and female Cynomolgus monkeys | Toxicology and Applied Pharmacology | Yafei Chen, J. D. Thurman et al. | 11 |
| 2 | A defense of 'risk-benefit' terminology | Lab Animal | Lewis B. Kinter, David K. Johnson | 4 |
| 3 | Safety pharmacology in 2010 and beyond: Survey of significant events of the past 10 years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society | Journal of Pharmacological and Toxicological Methods | Alan Bass, Hugo M. Vargas et al. | 8 |
| 4 | In vivoandin vitroliver and gill EROD activity in rainbow trout (Oncorhynchus mykiss) exposed to the beta‐blocker propranolol | Environmental Toxicology | Matthew J. Winter, Duane B. Huggett et al. | 26 |
| 5 | Drugs effects on ventricular repolarization: A critical evaluation of the strengths and weaknesses of current methodologies and regulatory practices | Journal of Pharmacological and Toxicological Methods | Alan Bass, Gordon F. Tomaselli et al. | 29 |
| 6 | Origins, practices and future of safety pharmacology | Journal of Pharmacological and Toxicological Methods | Alan Bass, Lewis B. Kinter et al. | 50 |
| 7 | Safety pharmacology and risk assessment | Fundamental and Clinical Pharmacology | Lewis B. Kinter, Jean‐Pierre Valentin | 26 |
| 8 | Pharmacokinetics and Hepatic Disposition of Bis[1-(ethoxycarbonyl)propyl]5-acetylamino-2,4,6-triiodoisophthalate in Rats and Isolated Perfused Rat Livers | Drug Metabolism and Disposition | Edward R. Bacon, C D Black et al. | 6 |
| 9 | Anomalous antidiuretic activity of antidiuretic hormone antagonists | Biochemical Pharmacology | Lewis B. Kinter, S Caltabiano et al. | 16 |
| 10 | Characterization of the renal handling of p-aminohippurate (PAH) in the beagle dog (Canis familiaris) | General Pharmacology The Vascular System | William A. Mann, Lewis B. Kinter | 7 |
| 11 | Characterization of the hemodynamic activities of fenoldopam and its enantiomers in the dog | Chirality | Lewis B. Kinter, William A. Mann et al. | 5 |
| 12 | Effect of a selective V1 vasopressin receptor antagonist on the sequelae of endotoxemia in the conscious rat. | PubMed | J. Egan, M Jugus et al. | 3 |
| 13 | Vasopressin receptor antagonism in rhesus monkey and man: stereochemical requirements | European Journal of Pharmacology | David P. Brooks, Paul F. Koster et al. | 7 |
| 14 | Noncyclic vasopressin analogs are effective diuretics in conscious rats. | Journal of Pharmacology and Experimental Therapeutics | Catherine Uyehara, S Caltabiano et al. | 1 |
| 15 | A minor modification of residue 1 in potent vasopressin antagonists dramatically reduces agonist activity | Journal of Medicinal Chemistry | William F. Huffman, B Brickson et al. | 7 |
| 16 | SK&F 105494 is a potent antidiuretic hormone antagonist in the rhesus monkey (Macaca mulatta). | PubMed | David P. Brooks, Paul F. Koster et al. | 16 |
| 17 | Dicarbavasopressin antagonist analogs exhibit reduced in vivo agonist activity | Journal of Medicinal Chemistry | M. Lane Moore, Christine R. Albrightson et al. | 7 |
| 18 | Renal imaging studies at 1.5 and 9.4 T: Effects of diuretics | Magnetic Resonance in Medicine | Susanta K. Sarkar, George Holland et al. | 6 |
| 19 | Potent vasopressin antagonist modified at the carboxy-terminal tripeptide tail | Journal of Medicinal Chemistry | Fadia E. Ali, William F. Huffman et al. | 2 |
| 20 | The Renin Angiotensin System in Conscious Brattleboro Strain Rats | Kidney & Blood Pressure Research | Lewis B. Kinter, Walter Flamenbaum et al. | 12 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.